insights_auto
Mtazamo: Thamani itaongezeka kwa asilimia 28.0·Thamani itapungua kwa asilimia 4.0
Nenda kwenye kichupo cha uchanganuzichevron_right
GSK:NYSE
GSK plc
US$ 48.58
arrow_downward
-1.36%(-0.67) Siku 1
US$ 48.58
0.00% (0.00)
bedtimeBaada ya saa
Imefungwa: 18 Nov, 16:00:02 GMT -5 · USD
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya GSK...
Fungua
US$ 49.03
Juu
US$ 49.49
Chini
US$ 48.54
Mtaji wa soko
98.33B
Wastani wa kiasi cha mauzo
4.82M
Kiasi cha mauzo ya hisa
2.20M
Gawio
3.78%
Mgawo wa faida wa kila robo mwaka
US$ 0.46
Tarehe ya kutojumuisha gawio
12 Nov 2026
Uwiano wa bei ya hisa na mapato kwa kila hisa
17.22
Juu kwa wiki 52
US$ 61.70
Chini kwa wiki 52
US$ 45.80
EPS
US$ 2.82
Beta
0.20
Hisa za wawekezaji
2.02B
Idadi ya wafanyakazi
elfu 67
Fungua
US$ 49.03
Juu
US$ 49.49
Chini
US$ 48.54
Mtaji wa soko
98.33B
Wastani wa kiasi cha mauzo
4.82M
Kiasi cha mauzo ya hisa
2.20M
Gawio
3.78%
Mgawo wa faida wa kila robo mwaka
US$ 0.46
Tarehe ya kutojumuisha gawio
12 Nov 2026
Uwiano wa bei ya hisa na mapato kwa kila hisa
17.22
Juu kwa wiki 52
US$ 61.70
Chini kwa wiki 52
US$ 45.80
EPS
US$ 2.82
Beta
0.20
Hisa za wawekezaji
2.02B
Idadi ya wafanyakazi
elfu 67
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
Zacks
·
saa 11 zilizopita
GSK Wins FDA Approval for Nuvalent-Acquired Nelkarmi in Lung Cancer
Benzinga
·
saa 12 zilizopita
GSK Marks Second Lung Cancer Drug Approval This Year
Traders Union
·
saa 19 zilizopita
FDA approval coincides with flat GSK stock price as sellers maintain pressure
News Corp
·
saa 20 zilizopita
GSK Gets FDA Approval for New Lung-Cancer Drug
Wasifu
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
Kuhusu GSK plc
Afisa Mkuu Mtendaji (CEO)Emma Walmsley | Emma Walmsley
Wafanyakazielfu 66.8
Lilianzishwa27 Des 2000
Makao makuu-
SektaHealth Care
Sekta-
Tovutigsk.com